LDLR and Hypercholesterolemia: However, to our surprise, we have been able to identify just one study in mice that aimed to prove that CRISPR-based gene editing is able to reverse hypercholesterolemia resulting from a functional defect in the LDL receptor, i.e., a E208X loss-of-function mutation [16].